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Guanidinoacetate methyltransferase (GAMT) deficiency is an inherited neurometabolic disorder biochemically characterized by tissue
accumulation of guanidinoacetate (GAA) and depletion of creatine. Affected patients present epilepsy and mental retardation whose etiopathogeny
is unclear. In a previous study we showed that instrastriatal administration of GAA caused a reduction of Na+,K+-ATPase and creatine kinase (CK)
activities, as well as an increase in TBARS (an index of lipid peroxidation). In the present study we investigated the in vitro and in vivo effects of
GAA on glucose uptake from [U-14C] acetate (citric acid cycle activity) and on the activities of complexes II, II–III, III and IV of the respiratory
chain in striatum of rats. Results showed that 50 and 100 μM GAA (in vitro studies) and GAA administration (in vivo studies) significantly
inhibited complexes II and II–III, respectively, but did not alter complexes III and IV, as well as CO2 production. We also studied the influence of
taurine or vitamins E and C on the inhibitory effects caused by intrastriatal administration of GAA on complexes II and II–III, Na+,K+-ATPase and
CK activities, and on TBARS in rat striatum. Pre-treatment with taurine and vitamins E and C revealed that taurine prevents the effects of
intrastriatal administration of GAA on the inhibition of complex II, complex II–III, and Na+,K+-ATPase activities. Vitamins E and C prevent the
effects of intrastriatal administration of GAA on the inhibition of CK and Na+,K+-ATPase activities, and on the increase of TBARS. The data
suggest that GAA in vivo and in vitro treatment disturbs important parameters of striatum energy metabolism and that oxidative damage may be
mediating these effects. It is presumed that defects in striatum bioenergetics might be involved in the pathophysiology of striatum damage
characteristic of patients with GAMT-deficiency.
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Guanidinoacetate (GAA) is the immediate precursor of
creatine, being mainly synthesized in the kidney from arginine
and glycine by glycine amidinotransferase. It is then transported
by creatine transporters to various tissues, including brain and
liver, where it is methylated to creatine by guanidinoacetate
methyltransferase (GAMT). GAMT-deficiency is an inherited
metabolic disease biochemically characterized by tissue accu-⁎ Corresponding author. Tel.: +55 51 316 5573; fax: +55 51 3316 5535.
E-mail address: wyse@ufrgs.br (A.T.S. Wyse).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.02.005mulation of GAA and depletion of creatine. Affected patients
present neurological symptoms, including muscular hypotonia,
involuntary extrapyramidal movements and epilepsy [1]. The
diagnosis is based on excessive levels of GAA in body fluids
of the affected patients, which is a pathognomonic feature of
GAMT-deficiency [1].
Neurological dysfunction is commonly found in human
GAMT-deficiency, but the exact mechanisms underlying brain
damage in this disease are not well established. However, at the
present the neurological symptoms of the affected patients have
been mainly attributed to creatine deficiency, although GAA
accumulationmay play a role in this process. This is in accordance
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GAA is probably epileptogenic in man. In this context, it was
demonstrated that GAA alters neurotransmission [3] and
decreases membrane fluidity [4]. It should be however em-
phasized that creatine deprivation is highly neurotoxic per se, as
evidenced by the serious neurological dysfunction affecting
patients with AGAT deficiency and creatine transporter de-
ficiency in which there is no accumulation of GAA [5,6].
Tissues with high energy requirement, such as the brain, are
more susceptible to damage under situations of reduced aerobic
metabolism [7]. In this context, impairment of energy metabo-
lism caused bymitochondrial dysfunction has been implicated in
the pathogenesis of a number of neurological conditions, in-
cluding dementia, cerebral ischemia, Alzheimer's disease and
Parkinson's disease [8–12]. To the best of our knowledge, there
is little information associating GAA and energy metabolism.
Schmidt and colleagues [13] recently showed that the knockout
mice for GAMT presented an increase of complex V activity,
suggesting that this effect was a compensation mechanism for
energy impairment. In addition, recent reports from our
laboratory showed that intrastriatal administration of GAA
inhibits Na+,K+-ATPase and creatine kinase (CK) activities in
rat striatum [14].
On the other hand, the central nervous system (CNS) is highly
sensitive to oxidative stress due to its high oxygen consumption,
its high iron and lipid contents, especially polyunsaturated fatty
acids, and the low activity of antioxidant defenses [15]. In this
context, we have previously demonstrated that GAA induced
lipid peroxidation in the brain [14].
Therefore, in the present study the main objective was to
investigate the in vitro and in vivo effects of GAA on CO2
production from [U-14C] acetate and on the activities of
complexes II, II–III, III and IV of the respiratory chain in rat
striatum. Since vitamins E and C and taurine have antioxidant
properties [16–18] and taurine is neuroprotective [19,20] and
has an antiepileptic action in experimental models [21] and in
humans [22], we also evaluated the in vivo influence of taurine
and vitamins E and C on the inhibition of the activities of some
complexes of the respiratory chain caused by GAA, as well as of
Na+,K+-ATPase and CK, which were previously shown to be
inhibited by GAA. Striatum was used because patients with
GAMT-deficiency may present basal ganglia abnormalities [1].
2. Materials and methods
2.1. Animals and reagents
Sixty-day-oldWistar rats were obtained from the Central Animal House of the
Department ofBiochemistry, Instituto deCiências Básicas da Saúde,Universidade
Federal do Rio Grande do Sul, Porto Alegre, Brazil. The animals were maintained
on a 12:12 h light/dark cycle in an air-conditioned constant temperature (22 °C±
1 °C) colony room, with food and water ad libitum. All reagents used were of
analytical grade and purchased from Sigma Co. (St Louis, MO, USA).
2.2. In vivo studies
2.2.1. Guanidinoacetate administration
For the in vivo studies, surgery and intrastriatal infusion were performed as
described in Zugno et al. [14]. Sixty day-old rats were anesthetized with anintraperitoneal injection of ketamine plus xylazine (100 mg/kg and 14 mg/kg,
respectively). The head of the animals was fixed in a stereotaxic apparatus, the
skin of the skull was removed and a 27-gauge 9-mm guide cannula was then
placed above the striatum (AP: −0.5 mm; L: −2.5 mm; DV: −2.5 mm) [23]. The
cannula was fixed with jeweler acrylic cement. Experiments were performed
48 h after surgery. A 30-gauge cannula was fitted into the guide cannula and
connected by polyethylene tube to a 5 μL Hamilton microsyringe. The tip of the
infusion cannula protruded 1.0 mm beyond the guide cannula towards the
striatum. The animals were divided into two groups: group 1 (control group), rats
that received saline solution; group 2 (GAA-treated), rats that received 10 μM of
GAA solution (0.02 nmol/striatum). Two μL of saline or GAA solution was
administered intrastriatally during 2 min. The needle was left in place for another
1 min before being softly removed, so that the total procedure lasted 3 min. The
correct position of the needle was tested by injecting 0.5 μL of methylene blue
(4% in saline solution). The animals were killed by decapitation without
anesthesia 30 min after injection. The experimental protocol was approved by
the Ethics Committee for animal research of the Universidade Federal do Rio
Grande do Sul, Porto Alegre, Brazil and followed the NIH Guide for the Care
and Use of Laboratory Animals (NIH publication 85-23, revised 1985). All
efforts were made to minimize the number of animals used and their suffering.
2.2.2. Taurine and vitamins E and C administration
In some experiments the animals were pretreated during 7 days with daily
intraperitoneal administration of alpha-tocopherol (40 mg/kg) and ascorbic acid
(100 mg/kg) or taurine (50 mg/kg). Controls animals received saline. Doses of
vitamins E and C and taurine were chosen according to Wyse et al. [24] and
Sener [18], respectively. Animals were sacrificed by decapitation without
anesthesia 30 min after the intrastriatal injection of GAA.
2.2.3. Tissue preparation
The brain was rapidly excised on a Petri dish placed on ice and the striatum
was dissected, weighed and kept chilled until homogenizationwith a ground glass
type Potter–Elvehjem homogenizer in the specific buffer used for each technique.
For the determination of the electron transfer chain complexes and CK
activities, the striatum was homogenized in 20 volumes of SETH buffer, pH 7.4
(250 mM sucrose, 2 mM EDTA, 10 mM Trizma base, and 50 IU/mL heparin).
The homogenates were centrifuged at 800×g for 10 min at 4 °C. The pellet was
discarded and the supernatants, a suspension of mixed and preserved organelles,
including mitochondria, kept at −70 °C until determination of the enzyme
activities. The maximal period between supernatant preparation and enzyme
analysis was always less than 7 days.
For Na+,K+-ATPase activity measurement, synaptic plasma membranes
were prepared according to the method of Jones and Matus [25], with some
modifications [26]. The homogenate was centrifuged at 1000×g for 20 min and
the supernatant removed and centrifuged at 12,000×g for a further 20 min. The
pellet was then resuspended in hypotonic buffer (5.0 mM Tris–HCl buffer, pH
8.1), incubated at 0 °C for 30 min, and applied on a discontinuous sucrose
density gradient consisting of successive layers of 0.3, 0.8 and 1.0 M. After
centrifugation at 69,000×g for 2 h, the fraction at the 0.8–1.0 M sucrose
interface was taken as the membrane enzyme preparation.
For the 14CO2 production assay, the striatumwas homogenized (1:10, w/v) in
Krebs–Ringer bicarbonate buffer pH 7.4 using an ice-chilled glass homogenizing
vessel at 900 rpm. Total homogenates were used in these experiments.
2.3. In vitro studies
For the in vitro studies, striatum from 60-day-old non-treated rats was
dissected and homogenized in a similar manner as that for the in vivo
experiments to obtain supernatants. The supernatants were then incubated in the
presence of 10, 30, 50 or 100 μM GAA.
2.4. Determination of the respiratory chain complexes activities
Mitochondrial respiratory chain enzyme activities (complexes II, III, II–III
and IV) were measured in striatum supernatants 30 min after GAA or NaCl
intrastriatal injection. The protein concentration in the supernatants varied from
1.5 to 4.0 mg protein/mL in all experiments. The activities of succinate: DCIP-
oxidoreductase (complex II) and succinate: cytochrome c oxidoreductase
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The activity of ubiquinol: cytochrome c oxidoreductase (complex III) was
assayed according to themethod described byBirch-Machin et al. [28] and that of
cytochrome c oxidase (complex IV) according to Rustin et al. [29]. The methods
described to measure these activities were slightly modified, as described in
details in previous reports [30,31]. The activities of the respiratory chain
complexes were expressed as nmol/min mg protein.
For the in vitro studies, 10, 30, 50 or 100 μMGAAwas supplemented to the
incubation medium, whereas the control group did not contain the metabolite.
2.5. Creatine kinase (CK) activity assay
CK activity was measured in striatum supernatants 30 min after GAA or
NaCl intrastriatal injection in a reaction mixture consisting of 60 mM Tris–HCl,
pH 7.5, containing 7 mM phosphocreatine, 9 mM MgSO4, 0.625 mM lauryl
maltoside and approximately 0.4–1.2 μg protein in a final volume of 100 μL.
For the in vitro studies, 10, 30, 50 or 100 μM GAA was supplemented to the
incubation medium, whereas the control group did not contain the metabolite.
After 10 min of pre-incubation at 37 °C, the reaction was started by the additionFig. 1. Effect of intrastriatal administration of guanidinoacetate on complex II (A),
production (E) in striatum from 60-day-old rats. Values are mean±standard deviati
p<0.01 (Duncan's multiple range test).of 0.3 μmol ADP. The reaction was stopped after 10 min by addition of 1 μmol
of p-hydroxymercuribenzoic acid. The creatine formed was estimated according
to the colorimetric method of Hughes [32] with slight modifications as described
previously [33]. The color was developed by the addition of 100 μL 2%
α-naphtol and 100 μL 0.05% diacetyl in a final volume of 1 mL and read
spectrophotometrically at 540 nm after 20 min. Results were expressed as μmol
creatine/min/mg protein.
2.6. Na+,K+-ATPase activity assay
The reaction mixture for Na+, K+-ATPase assay contained 5.0 mM MgCl2,
80.0 mMNaCl, 20.0 mMKCl and 40.0 mMTris–HCl, pH 7.4, in a final volume
of 200 μL. The reaction was initiated by addition of ATP to a final concentration
of 3.0 mM. Controls were carried out under the same conditions with the
addition of 1.0 mM ouabain. Na+, K+-ATPase activity was calculated by the
difference between the two assays according to the method of Wyse and
colleagues [34]. Released inorganic phosphate (Pi) was measured by the method
of Chan et al. [35]. Specific activity of the enzyme was expressed as nmol Pi
released per min per mg of protein.complex II–III (B), complex III (C) and complex IV (D) activities and on CO2
on for five to six independent experiments per group. *Different from control,
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14C]acetate
For the experiments designed to evaluate 14CO2 production, the animals
were sacrificed 30 min after intrastriatal GAA or NaCl injection. The striatum
homogenates containing 1.5–2 mg protein were added to small flasks (11 cm3).
Flasks were pre-incubated in a metabolic shaker at 37 °C for 15 min. After pre-
incubation, 0.1 μCi [1-14C]-acetate and 1.0 mM of unlabeled acetate were added
to the incubation medium. The flasks were gassed with a O2:CO2 (95:5) mixture
and sealed with rubber stoppers and Parafilm M. Glass center wells containing a
folded 65 mm/5 mm piece of Whatman 3 filter paper were hung from the
stoppers. After 60 min of incubation at 37 °C, 0.1 mL of 50% trichloroacetic
acid was added to the medium and 0.1 mL of benzethonium hydroxide was
added to the center wells with a needle introduced through the rubber stopper.
The flasks were left to stand for 30 min to complete 14CO2 trapping and thenFig. 2. Effect of guanidinoacetate addition on the assays of complex II (A), complex I
in striatum from 60-day-old rats. Values are mean±standard deviation for five to six
multiple range test).opened. The filter papers were removed and added to vials containing
scintillation fluid, and radioactivity was measured [36]. Results correspond to
pmol 14CO2/h/mg protein and were expressed as percentage of controls.
2.8. Protein determination
Protein content was measured by the method of Lowry et al. [37], using
bovine serum albumin as standard.
2.9. Statistical analysis
Data were analyzed by the Student's t-test or by one-way analysis of variance
(ANOVA) followed by the Duncan multiple range test when the F-test was
significant. Pearson linear regression coupled to ANOVAwas also used to verifyI–III (B), complex III (C) and complex IV (D) activities and CO2 production (E)
independent experiments per group. *Different from control, p<0.01 (Duncan's
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Package for the Social Sciences (SPSS) software. A value of p<0.05 was
considered to be significant.Fig. 4. Effect of pretreatment of administration with taurine and vitamins E and
C on the inhibition caused by intrastriatal administration of guanidinoacetate on
Na+,K+-ATPase (A) and creatine kinase (B) activities in striatum from 60-day-
old rats. Values are mean±standard deviation for five to seven independent3. Results
First, we tested the effect of intrastriatal administration of
GAA on CO2 production from acetate (citric acid cycle activity)
and on complexes II, II–III, III and IVactivities of the respiratory
chain in striatum of 60-day-old rats. Fig. 1 shows that GAA
significantly inhibited (20–25%) complex II [t(8)=6.74,
p<0.01] (A) and complex II–III [t(8)=3.22, p<0.01] (B), but
did not alter complexes III (C) and IVactivities (D), neither CO2
production (E). We also investigated the in vitro effects of GAA
on the same parameters studied in vivo. Fig. 2 shows that 50–
100 μMofGAA significantly inhibited complex II (around 25%)
[F(4,20)=4.73, p<0.01] (A), but did not alter complexes II–III
(B), III (C) and IV activities (D), neither CO2 production (E).
A previouswork from our group has shown that GAA inhibits
Na+,K+-ATPase and CK activities in rat striatum [14]. Therefore,
since GAA induces oxidative stress [38,39], we also examined
the influence of taurine and vitamins E and C, which have
antioxidant properties, on the inhibitory effects caused by
intrastriatal administration of GAAon complexes II and complex
II–III activities, as well as on Na+,K+-ATPase and CK activities.
Results showed that taurine and vitamins E and C administration
did not alter per se the parameters studied, but only taurine
prevented the inhibition of the activities of complexes IIFig. 3. Effect of pretreatment with taurine and vitamins E and C on the inhibition
caused by intrastriatal administration of guanidinoacetate on complex II (A) and
complex II–III (B) activities in striatum from 60-day-old rats. Values are mean±
standard deviation for five to seven independent experiments per group.
⁎Different from control, p<0.01 (Duncan's multiple range test). GAA=guani-
dinoacetate; Tau=taurine; Vits=vitamins E andC; GAA+Tau=guanidinoacetate
plus Taurine; GAA+Vits=guanidinoacetate plus vitamins E and C.
experiments per group. *Different from control, p<0.01 (Duncan's multiple
range test). GAA=guanidinoacetate; Tau=taurine; Vits=vitamins E and C;
GAA+Tau=guanidinoacetate plus Taurine; GAA+Vits=guanidinoacetate plus
vitamins E and C.[F(5,36) = 3.98, p<0.01] (A) and II–III [F(5,30) = 6.04,
p<0.01] (B) caused by GAA (Fig. 3). Furthermore, taurine
and vitamins E plus C prevented the inhibitory effects caused by
GAA on Na+,K+-ATPase activity [F(5,24)=7.30, p<0.01] (Fig.
4A), whereas vitamins E plus C prevented the GAA-induced
inhibition on CK [F(5,30)=3.97, p<0.01] (Fig. 4B) activity.
Next, we evaluated the effect of taurine or vitamins E and C
administration on GAA-induced in vivo increase of the
thiobarbituric acid reactive substances (TBARS) measurement,
an index of lipid peroxidation in rat striatum. Fig. 5 shows that
GAA significantly increased TBARS and vitamins E and C, but
not taurine, prevented this effect [F(5,22)=7.821, p<0.001].
4. Discussion
GAMT-deficiency is an inherited metabolic disease bio-
chemically characterized by tissue accumulation of GAA.
Affected patients present neurological damage whose under-
lying mechanisms are poorly known [1]. In a previous work we
demonstrated that GAA inhibits Na+,K+-ATPase and CK
activities in rat striatum. In the present study we investigated
the in vivo and in vitro effects of GAA on some parameters of
energy metabolism, including CO2 production from [U-
14C]
acetate (citric acid cycle activity) and the activities of complexes
Fig. 5. Effect of pretreatment with administration of taurine and vitamins E and
C on the increase of TBARS caused by intrastriatal administration of
guanidinoacetate in striatum from 60-day-old rats. Values are mean±standard
deviation for four to six independent experiments per group. *Different from
control, p<0.01 (Duncan's multiple range test). GAA=guanidinoacetate;
Tau= taurine; Vits=vitamins E and C; GAA+Tau=guanidinoacetate plus
Taurine; GAA+Vits=guanidinoacetate plus vitamins E and C.
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verified that intrastriatal administration of GAA significantly
reduced complexes II and II–III and did not affect complexes III
and IV. We also observed that complex II, but not the other
complexes analyzed, was inhibited when exposed to 50 and
100 μM of GAA in vitro. These results indicate that GAA is a
selective inhibitor of complex II of the respiratory chain.
Furthermore, CO2 production was also not affected in vivo and
in vitro by GAA, indicating that the activity of the citric acid
cycle was not disturbed by this organic acid.
Considering that GAA is a compound that induces oxidative
stress [20,39] and that complex II, Na+,K+-ATPase and CK
activities are vulnerable to free radical attack [40–42], it is
possible that the reduction of the enzymatic activities caused by
GAA administration, as demonstrated in a previous work for
Na+,K+-ATPase and CK [14] and in the present study for
complex II, could occur through oxidative damage. To test this
hypothesis, we pretreated the animals during a week with taurine
or vitamins E and C and injected GAA afterwards. Taurine was
previously demonstrated to possess antioxidant activities
[18,19] and to be a neuroprotector [43]. In this context, we
have recently demonstrated that taurine prevents the inhibition
of Na+,K+-ATPase activity caused by GAA in vitro [20].
Furthermore, vitamins E and C are classic antioxidants [18].
Vitamin E is a lipid-soluble vitamin that interacts with cell
membranes, traps free radicals and interrupts the oxidative chain
that damages cells [44,45], preventing the uncontrolled
propagation of lipid peroxidation by free radicals [45]. The
resultant tocopheroxil radical requires ascorbate (vitamin C) for
its regeneration back to reduced tocopherol [46,47].
Our results showed that taurine prevented the inhibitory
effect caused by intrastriatal administration of GAA on the
activities of complexes II and II–III. Furthermore, the inhibition
of Na+,K+ATPase activity caused by intrastriatal administration
of GAA was prevented by both taurine and vitamins E and C.Finally, we found that the inhibition of the activity of CK as well
as the increase of TBARS caused by GAA was prevented by
pre-treatment with vitamins E and C, but not by taurine. The
exact mechanisms underlying taurine effects are not clearly
understood. However, strong evidences show that taurine acts
as a reactive oxygen species and nitrogen radical scavenger [48]
and also as a membrane stabilizer [49]. Vitamins E and C are
known to prevent the propagation of lipid peroxidation by free
radicals [45].
Taken together, the present data indicate that disturbances of
bioenergetics and oxidative stress are interrelated mechanisms
underlying the neurological dysfunction characteristic of
GAMT-deficient patients. However, it should be emphasized
that since we did not measure brain GAA concentrations after
GAA administration, we cannot establish precisely whether our
present results of altered oxidative metabolism are of relevance
for the GAMT deficient patients.
In conclusion, we demonstrated here that the respiratory
chain activity is compromised in vivo and in vitro by GAA
probably via oxidative attack. Considering previous reports
demonstrating that other important enzyme activities of the
CNS, i.e. Na+,K+-ATPase and CK, were also inhibited by GAA,
it is conceivable that brain accumulation of GAA may disturb
CNS functioning. However, it should be emphasized that
creatine deficiency is neurotoxic per se, since patients with
AGAT deficiency and creatine transporter deficiency in which
there is no accumulation of GAA present serious neurological
dysfunction [5,6]. The present findings may explain, at least in
part the neurotoxicity caused by GAA in patients affected by
GAMT-deficiency. Our results also suggest that the administra-
tion of antioxidants should be considered as an adjuvant therapy
to specific diets or to other pharmacological interventions.
However, more studies must be conducted before administration
of antioxidants is given to GAMT-deficient patients.
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